fda semaglutide warning news october 2025 Novo Nordisk expands legal action to protect US patients from unsafe, non- FDA-approved compounded "semaglutide" Semaglutide Patient Safety Updates |

This provides a biological basis for considering whether pharmacological GLP-1 therapies, which achieve much higher systemic levels, could also reach the joint and potentially have local effects. Additionally, scientists found that the level of GLP-1 hormone in the synovial fluid is directly tied to the levels in the blood of arthritis patients

This model eliminates the need for waiting rooms and allows for consistent, ongoing support

(2020) 158:19992014.e1

Most people find that a seven-day gap between their final dose of Mounjaro and their first dose of Wegovy is enough to reduce the risk of overlapping side effects, such as bloating and nausea